WebFeb 13, 2024 · Darzalex (daratumumab) injection is a human CD38-directed monoclonal antibody indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory … WebOct 25, 2016 · Daratumumab, also known as Darzalex, DARA, or Dara-T, is a new medication recently approved in the US by the FDA to treat multiple myeloma. …
Daratumumab for the Treatment of Multiple Myeloma: A Review …
WebDarzalex is often given with other medications to treat multiple myeloma, and the duration of treatment can depend on the tolerability of the whole regimen, not just Darzalex. Clinical trials have reported treatment durations of up to 25.3 months (range 0.1 month to 40.44 months). What is the half life of Daratumumab? WebAnti-CD38 monoclonal antibodies are a treatment for multiple myeloma CD38 is an integral membrane protein that is highly expressed on myeloma cells that has been shown to be … canada money market rates
HCP Website DARZALEX® (daratumumab) & DARZALEX …
WebDARZALEX is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one ... Web• Interference with cross-matching and red blood cell antibody screening: Type and screen patients prior to starting treatment. Inform blood banks that a patient has received … WebMar 14, 2024 · Daratumumab can interfere with blood type testing (cross-matching and antibody screening). If you require a blood transfusion, be sure your provider and the … canada ministry of the environment